";s:4:"text";s:4157:"Such risks and uncertainties include, among others, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the expectations for regulatory communications, submissions and approvals; the continued development of the gene therapy platform; Voyager’s scientific approach and general development progress; Voyager’s ability to transfer technology successfully to contract development and manufacturing organizations and the ability of such organizations to manufacture at clinical and commercial scale; and the availability or commercial potential of Voyager’s product candidates. "“We are thrilled to begin working with Voyager and to be a contributor to the development of their gene therapy pipeline,” said Gerry Farrell, chief operating officer of Fujifilm Diosynth Biotechnologies, Texas.
For more information, please visit This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws.
For example, all statements Voyager makes regarding the initiation, timing, progress and reporting of results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully initiate, enroll and complete, clinical trials, the potential clinical utility of its product candidates, its ability to continue to develop its gene therapy platform, its ability to develop manufacturing capability for its products and successfully transition its manufacturing process including the transition of its baculovirus/Sf9 production system to Brammer and Fujifilm, its ability to perform under existing collaborations with, among others, Sanofi Genzyme and AbbVie and manufacturers Brammer and Fujifilm and to add new programs to its pipeline, its ability to enter into new partnerships or collaborations, the sufficiency of its cash resources and the regulatory pathway of, and the timing or likelihood of its regulatory filings and approvals for, any of its product candidates, are forward looking. CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie. Voyager’s manufacturing platform utilizes a baculovirus/Sf9 cell production process that enables the production of … Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Several members of Voyager Therapeutics’ current production team invented and developed the baculovirus AAV production system, a technology for producing AAV vectors at scale in insect-derived cells, which we use and have continued to improve. Find the latest Voyager Therapeutics, Inc. (VYGR) stock quote, history, news and other vital information to help you with your stock trading and investing. Manufacturing The ability to produce and manufacture high-quality AAV vectors at scale is a critical success factor in AAV gene therapy.